A randomized study of rotigotine dose response on 'off' time in advanced Parkinson's disease

Academic Article

Abstract

  • BACKGROUND: Previous phase III studies in patients with advanced Parkinson's disease (PD) not adequately controlled on levodopa demonstrated significant reduction of 'off' time with rotigotine transdermal system up to 16 mg/24 h. However, the minimal effective dose has not been established.
  • Published In

    Digital Object Identifier (doi)

    Author List

  • Nicholas AP; Borgohain R; ChanĂ¡ P; Surmann E; Thompson EL; Bauer L; Whitesides J; Elmer LW
  • Start Page

  • 361
  • End Page

  • 373
  • Volume

  • 4
  • Issue

  • 3